iBio Q1 FY27 net loss widens 32% year over year to $7.55 million

• iBio’s Q1 FY27 net loss widened 32% year over year to $7.55 million.
• Revenue rose year over year to $1.08 million.
• R&D expenses climbed 87% year over year to $6.65 million, primarily due to increased spending on consultants and outside services.
• Cash, cash equivalents and investments in debt securities totaled $76.7 million at September 30, 2026.
• IBIO-600 interim Phase 1 data are expected in first-quarter 2027; IBIO-610 first-in-human trials are planned for first-half 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101630PRIMZONEFULLFEED9874607) on November 10, 2026, and is solely responsible for the information contained therein.